Blood-based transplant monitoring test
Post-transplant organ rejection monitoring
CommercialAvailable
Key Facts
Indication
Post-transplant organ rejection monitoring
Phase
Commercial
Status
Available
About Insight Molecular Diagnostics
iMDx is a U.S.-based public company advancing precision medicine through innovative, blood-based molecular diagnostics in transplantation and oncology. Its strategic rebrand from Oncocyte solidified a focus on commercializing and developing tests for transplant rejection monitoring and cancer therapy guidance. The company's core strategy involves leveraging its proprietary cfDNA analysis platform to decentralize testing, making critical diagnostics more accessible to healthcare systems and patients. Key achievements include the commercial launch of a transplant monitoring test and the assembly of a seasoned leadership team with deep diagnostics and commercialization expertise.
View full company profile